This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chiou, C. C. Articles by Walsh, T. J. Search for Related Content PubMed PubMed Citation Articles by Chiou, C. C. Articles by Walsh, T. J.

New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer

National Cancer Institute, Bethesda, Maryland, USA

Correspondence: Thomas J. Walsh, M.D., Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health Bldg. 10, Rm. 13N240, 10 Center Drive, Bethesda, Maryland 20892, USA. Telephone: 301-402-0023; Fax: 301-402-0575; e-mail: walsht{at}pbmac.nci.nih.gov

Invasive fungal infections have emerged as important causes of morbidity and mortality in profoundly immunocompromised patients with cancer. Current treatment strategies for these infections are limited by antifungal resistance, toxicity, drug interactions, and expense.

In order to overcome these limitations, new antifungal compounds are being developed, which may improve our therapeutic armamentarium for prevention and treatment of invasive mycoses in high-risk patitnts with neoplastic diseases.

Key Words. Triazoles • Voriconazole • Posaconazole • Ravuconazole • Echinocondins

This article has been cited by other articles:

				V Yadav, R Mandhan, R. Dabur, A K Chhillar, J Gupta, and G L Sharma A fraction from Escherichia coli with anti-Aspergillus properties J. Med. Microbiol., April 1, 2005; 54(4): 375 - 379. [Abstract] [Full Text] [PDF]

				T. J. Walsh, M. O. Karlsson, T. Driscoll, A. G. Arguedas, P. Adamson, X. Saez-Llorens, A. J. Vora, A. C. Arrieta, J. Blumer, I. Lutsar, et al. Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2166 - 2172. [Abstract] [Full Text] [PDF]

				J. A. Dowell, W. Knebel, T. Ludden, M. Stogniew, D. Krause, and T. Henkel Population Pharmacokinetic Analysis of Anidulafungin, an Echinocandin Antifungal J. Clin. Pharmacol., June 1, 2004; 44(6): 590 - 598. [Abstract] [Full Text] [PDF]

				V. Petraitis, R. Petraitiene, A. H. Groll, K. Roussillon, M. Hemmings, C. A. Lyman, T. Sein, J. Bacher, I. Bekersky, and T. J. Walsh Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1857 - 1869. [Abstract] [Full Text] [PDF]

				C. C. Chiou, N. Mavrogiorgos, E. Tillem, R. Hector, and T. J. Walsh Synergy, Pharmacodynamics, and Time-Sequenced Ultrastructural Changes of the Interaction between Nikkomycin Z and the Echinocandin FK463 against Aspergillus fumigatus Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3310 - 3321. [Abstract] [Full Text] [PDF]